Survodutide

What is Survodutide?

Survodutide is an investigational injectable peptide being developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic liver disease. It is a dual agonist: one molecule that activates both the GLP-1 receptor and the glucagon receptor. That second target is what sets it apart from the GLP-1 drugs most people know. It is not approved anywhere. As of now it has strong phase 2 data and is in phase 3 trials, so treat it as a promising candidate, not a finished medicine.

How Survodutide works

GLP-1 receptor activation is the familiar mechanism: it curbs appetite, slows gastric emptying, and improves how the body handles glucose. Survodutide adds glucagon receptor activation on top. Glucagon is usually thought of as the hormone that raises blood sugar, but it also increases energy expenditure and pushes the liver to burn stored fat. Combining the two is the point: the GLP-1 side drives weight loss through reduced intake, while the glucagon side may boost calorie burn and directly target liver fat. That liver angle is why survodutide is being studied head-on for fatty liver disease, not just weight.

What the research shows

The data so far is phase 2, but it is real and controlled. In a randomized, placebo-controlled dose-finding trial in adults with obesity, the higher survodutide doses produced mean weight loss of about 19 percent at 46 weeks, with weight still declining at the end, which suggests the ceiling had not been reached. In a separate 48-week phase 2 trial in biopsy-confirmed MASH, up to roughly 62 percent of people on survodutide had improvement in MASH without worsening of fibrosis, compared with 14 percent on placebo. Phase 3 trials are ongoing to confirm whether these results hold at scale.

Dosage and how it is used

There is no approved dose because survodutide is not an approved drug. In trials it is given as a once-weekly subcutaneous injection, titrated up gradually over several weeks to limit gastrointestinal side effects, in the same way other incretin drugs are ramped. Any dosing figures come from clinical protocols, not a label, and it is only legitimately available inside a trial. Do not treat trial numbers as instructions.

→ How to reconstitute Survodutide: calculator, units to draw & storage

Side effects and safety

The side effect pattern in trials looks like the incretin-drug class: mostly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, worst during dose escalation and easing over time. The glucagon component raises questions the trials are still working through, such as effects on heart rate and blood sugar handling. Because it is investigational, its long-term safety is not established, and there is no approved-use safety record to lean on.

• Investigational only, with phase 2 evidence and phase 3 trials in progress.
• Side effects are mainly gastrointestinal and cluster during dose escalation.
• Not FDA-approved and only legitimately available in trials. Verify current status independently.

Frequently asked questions

References

• le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol, 2024.
• Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med, 2024.